TARGET’s AML researchers identified abundant expression of miR-106a, a marker for treatment resistance, in relapsed and refractory pediatric AML through a comprehensive miRNA profile to identify potential biomarkers as predictors for improved outcomes.
TARGET researchers performed comprehensive analysis of Wilms Tumors and identified convergence of numerous genetic changes on limited developmental pathways resulting in oncogenesis. Findings suggests targeting common pathways is better for intervention instead of individual gene mutations.
TARGET researchers perform the first comprehensive genomic study of T-lineage acute lymphoblastic leukemia (T-ALL) and identify a large number of unrecognized driver mutations in targetable pathways. These results have significant therapeutic weight in children with T-ALL.
TARGET investigators report on the key role that loss of TP53 plays in the development of anaplasia in Wilms tumors and may reflect the risk of relapse and death in children with this disease.
TARGET researchers performed genomic characterization of extra-cranial malignant rhabdoid tumors and found dysregulation of neural crest development genes.
Researchers used whole exome capture sequencing to compare biopsies from the same patient at diagnosis, remission and relapse, revealing that there is significant variability between these stages.
Researchers discover mutations in the MLLT1 gene in Wilms tumor that may help explain Wilms tumor development.
Investigators study the DNA variant in the LMO1 gene with leads to neuroblastoma development.
The authors analyzed a discovery set of 13 CCSKs for changes in chromosome copy number, mutations, rearrangements, global gene expression and global DNA methylation.